 long-term safeti efficaci zidovudin patient advanc human immunodefici viru diseas zidovudin epidemiolog studi group epidemiolog studi long-term safeti efficaci zidovudin patient advanc human immunodefici viru diseas data patient acquir immunodefici syndrom aid aids-rel complex count /L eighteen-month surviv cohort pretreat factor increas surviv time index diagnosi aids-rel complex hematocrit count /L high function statu time diagnosi aid treatment day proport hazard analysi develop seriou anemia signific factor earli death zidovudin high proport time chanc surviv anemia seriou leukopenia seriou anemia patient nonhematolog advers event uncommon unreport advers event